MX347533B - Celulas similares a tr1 que producen il-13, y su uso. - Google Patents

Celulas similares a tr1 que producen il-13, y su uso.

Info

Publication number
MX347533B
MX347533B MX2013000115A MX2013000115A MX347533B MX 347533 B MX347533 B MX 347533B MX 2013000115 A MX2013000115 A MX 2013000115A MX 2013000115 A MX2013000115 A MX 2013000115A MX 347533 B MX347533 B MX 347533B
Authority
MX
Mexico
Prior art keywords
cells
producing
human
low level
population
Prior art date
Application number
MX2013000115A
Other languages
English (en)
Spanish (es)
Other versions
MX2013000115A (es
Inventor
Foussat Arnaud
Brun Valérie
Bastian Hervé
Quattannens Brigitte
Original Assignee
Txcell *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell * filed Critical Txcell *
Publication of MX2013000115A publication Critical patent/MX2013000115A/es
Publication of MX347533B publication Critical patent/MX347533B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013000115A 2010-06-30 2011-06-30 Celulas similares a tr1 que producen il-13, y su uso. MX347533B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35988510P 2010-06-30 2010-06-30
EP10368030A EP2412802A1 (en) 2010-07-29 2010-07-29 IL-13 producing TR1-like cells and use thereof
PCT/IB2011/002269 WO2012001533A2 (en) 2010-06-30 2011-06-30 Il-13 producing tr1-like cells and use thereof

Publications (2)

Publication Number Publication Date
MX2013000115A MX2013000115A (es) 2013-09-13
MX347533B true MX347533B (es) 2017-05-02

Family

ID=43099691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000115A MX347533B (es) 2010-06-30 2011-06-30 Celulas similares a tr1 que producen il-13, y su uso.

Country Status (14)

Country Link
US (1) US20130101568A1 (enExample)
EP (2) EP2412802A1 (enExample)
JP (2) JP2013539356A (enExample)
KR (1) KR20130093083A (enExample)
CN (2) CN107189983A (enExample)
AU (1) AU2011273103B2 (enExample)
BR (1) BR112012033727A2 (enExample)
CA (1) CA2803779A1 (enExample)
CL (1) CL2012003705A1 (enExample)
MX (1) MX347533B (enExample)
NZ (1) NZ605088A (enExample)
RU (1) RU2013103765A (enExample)
WO (1) WO2012001533A2 (enExample)
ZA (1) ZA201209758B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106207A1 (en) * 2017-12-01 2019-06-06 General Electric Company Methods for cell enrichment and isolation
US11920119B2 (en) 2018-02-09 2024-03-05 Global Life Sciences Solutions Usa Llc Systems and methods for bioprocessing
US11932842B2 (en) 2018-02-09 2024-03-19 Global Life Sciences Solutions Usa Llc Bioprocessing apparatus
US12077743B2 (en) 2018-02-09 2024-09-03 Global Life Sciences Solutions Usa Llc Apparatus for fluid line management in a bioprocessing system
US10889792B2 (en) 2018-02-09 2021-01-12 Global Life Sciences Solutions Usa Llc Cell expansion vessel systems and methods
US12252682B2 (en) 2018-02-09 2025-03-18 Global Life Sciences Solutions Usa Llc System and method for fluid flow management in a bioprocessing system
CN113461822B (zh) * 2021-05-21 2022-11-11 深圳市新产业生物医学工程股份有限公司 Scl-70抗体或其结合片段、其筛选方法及包含其的检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP1248643B1 (en) * 2000-01-20 2005-08-17 YEDA RESEARCH AND DEVELOPMENT Co. LTD. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
CN101151275B (zh) * 2005-04-27 2013-07-10 金克克国际有限公司 用于降低细胞因子免疫原性和去除细胞表面标记的方法
US20100034782A1 (en) * 2006-05-31 2010-02-11 Nader Najafian Methods of Using Anti-Thymocyte Globulin and Related Agents
EP2032695B1 (en) * 2006-05-31 2018-08-15 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis

Also Published As

Publication number Publication date
AU2011273103B2 (en) 2015-04-16
MX2013000115A (es) 2013-09-13
US20130101568A1 (en) 2013-04-25
RU2013103765A (ru) 2014-08-10
CN107189983A (zh) 2017-09-22
NZ605088A (en) 2015-05-29
EP2412802A1 (en) 2012-02-01
JP2013539356A (ja) 2013-10-24
EP2588595A2 (en) 2013-05-08
CL2012003705A1 (es) 2013-12-13
AU2011273103A1 (en) 2013-01-17
WO2012001533A3 (en) 2012-06-07
BR112012033727A2 (pt) 2017-07-18
JP2017148042A (ja) 2017-08-31
CN103080303A (zh) 2013-05-01
CA2803779A1 (en) 2012-01-05
WO2012001533A2 (en) 2012-01-05
ZA201209758B (en) 2014-03-26
KR20130093083A (ko) 2013-08-21

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
PH12019502424A1 (en) Compositions and methods for immunotherapy
MY178142A (en) Anti-phf-tau antibodies and their uses
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
MX2020005143A (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
MX2015013104A (es) Composiciones y métodos para la inmunoterapia.
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX382772B (es) Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
MX2019005251A (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
PT2928923T (pt) Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
ECSP12012105A (es) Antídotos de Anticoagulantes
PH12013501323A1 (en) Anti-mesothelin antibodies and immunoconjugates
EP2850179A4 (en) FEEDER-FREE DISPOSAL OF HUMAN MADE PLURIPOTENTIAL STEM CELLS WITH SYNTHETIC MESSENGER RNA
CO6450619A2 (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
UY34185A (es) ?partículas cristalinas recubiertas con micelas de copolímeros, composiciones, proceso de preparación de dichas partículas y sus usos?.
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
IN2014DN07961A (enExample)
PH12014501240A1 (en) Film containing compositions
WO2012001533A3 (en) Il-13 producing tr1-like cells and use thereof
WO2014138733A3 (en) Compositions and methods for making human antibodies
HK1197560A (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer

Legal Events

Date Code Title Description
FG Grant or registration